Top View
- United States Securities and Exchange Commission Form
- Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
- Horizon Scanning Status Report December 2020
- Version 1; Peer Review: 1 Approved, 1 Approved with Reservations]
- View Annual Report
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Fedratinib (Inrebic®) (Updated November 2019)
- AHRQ Healthcare Horizon Scanning System – Status Update
- Tenncare Autoexempt List September 1, 2021 This Is a Current List of the Drugs and Supplies That Do Not Count Toward an Enrollee’S Monthly Drug Limit
- Inrebic (Fedratinib)
- Cardiotoxicity of Novel Targeted Hematological Therapies
- Inrebic (Fedratinib) Policy Number: C17941-A
- Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Novel Targeted Drugs Approved by the NMPA and FDA in 2019
- Inrebic® (Fedratinib) (Oral) Document Number: IH-0492 Last Review Date 10/26/2020 Date of Origin: 09/03/2019 Dates Reviewed: 09/2019, 11/2020
- Fedratinib in Patients with Myelofibrosis Previously Treated
- Oncology Agents Policy #: Rx.01.67
- Persistence of Myelofibrosis Treated with Ruxolitinib
- Ventegra Overview
- Chronic Neutrophilic Leukemia with Concurrent CSF3R And
- 1 Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant
- Polatuzumab Vedotin-Piiq
- FDA Requires Warnings About Increased Risk of Serious Heart
- List Item Applications for New Human
- Use of Antioxidants for the Neuro-Therapeutic Management of COVID-19
- The STAT3 Pathway As a Therapeutic Target in Head and Neck Cancer: Barriers and Innovations
- Fedratinib, a Newly Approved Treatment for Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Inrebic (Fedratinib)
- Inrebic, INN-Fedratinib
- Page 1 of 303 2020 Enhanced‐2 PDP Prior Authorization Criteria Effective 12/01/2020
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- S13054-020-03020-3.Pdf
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Oncology Oral, Hematologic Cancers Therapeutic Class Review (TCR)
- 16722836) Imatinib (Pubmed CID: 123596) in the Treatment of Urothelial Bladder Cancers
- Chemo Agents for Specific Cancers
- Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art
- Leukemia Insights Newsletter September 2020 MPN
- Rethinking JAK2 Inhibition: Towards Novel Strategies of More Specific and Versatile Janus Kinase Inhibition
- The Pharmaceutical Industry in 2019. an Analysis of FDA Drug Approvals from the Perspective of Molecules
- Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
- Publication Agenda CHMP 07-10 December 2020
- Patient Self-Reporting in the Evaluation of Cancer Drug Tolerability
- Public Assessment Report
- Open Full Page